Personnel exposure in labelling and administration of 177Lu- DOTA-D-Phe1-Tyr3-octreotide

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The introduction of peptide receptor radionuclide therapy, mainly performed with Y and 177Lu-labelled somatostatin analogues, has widened the therapeutic horizon of nuclear medicine.The handling of 177Lu-labelled pharmaceuticals implies an increase of the personnel exposure and this aspect is evaluated in this paper, in comparison with personal exposure in Y manipulation. MATERIALS AND METHODS: Personal dose measurements were performed during 26 177Lu-DOTATOC preparations by using a series of thin active layer LiF: Mg,Cu,P thermoluminescence dosimeters fixed at the operator's fingertips to evaluate the skin equivalent dose and by means of direct reading dosimeters positioned at the chest to evaluate the personal effective dose. Individual protection devices, such as shielded aprons and anti-X gloves, were also used. RESULTS: The 95th percentile of the skin equivalent dose distribution for 177Lu operations by using 0.20-mm anti-X gloves was 0.080 mSv/GBq for the chemist and 0.011 mSv/GBq for the physician, whereas the 75th percentile was 0.058 mSv/GBq for the chemist and 0.006 mSv/GBq for the physician. The use of the 0.25 mm Pb-equivalent anti-X apron halved the personal equivalent dose measured over the apron by a direct reading dosimeter. Skin doses were compared with Y-DOTATOC procedures: no relevant exposure reduction is observed for chemists, whereas doses are considerably lower during administration procedures performed by physicians. CONCLUSION: In this study, an evaluation of the skin equivalent doses during 177Lu-DOTATOC labelling and administration is presented. These data can be useful to assess the risk for workers in centres that are starting to implement PRRT using 177Lu. The use of appropriate protection devices and procedures allows the observance of International Commission for Radiological Protection dose limits for exposed workers.

Original languageEnglish
Pages (from-to)947-953
Number of pages7
JournalNuclear Medicine Communications
Volume32
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Octreotide
Skin
Physicians
Reading
Equipment and Supplies
Peptide Receptors
Nuclear Medicine
Somatostatin
Radioisotopes
Thorax
Therapeutics
Pharmaceutical Preparations
Radiation Dosimeters
DOTA(0)-Tyr(3)-177lu-octreotide

Keywords

  • Lu-DOTATOC
  • beta particles
  • DOTATOC
  • occupational exposure
  • radiation protection

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Personnel exposure in labelling and administration of 177Lu- DOTA-D-Phe1-Tyr3-octreotide. / Sghedoni, Roberto; Grassi, Elisa; Fioroni, Federica; Asti, Mattia; Piccagli, Vando; Versari, Annibale; Iori, Mauro.

In: Nuclear Medicine Communications, Vol. 32, No. 10, 10.2011, p. 947-953.

Research output: Contribution to journalArticle

@article{68e2b34221b449c084bab4f021d78dc4,
title = "Personnel exposure in labelling and administration of 177Lu- DOTA-D-Phe1-Tyr3-octreotide",
abstract = "OBJECTIVE: The introduction of peptide receptor radionuclide therapy, mainly performed with Y and 177Lu-labelled somatostatin analogues, has widened the therapeutic horizon of nuclear medicine.The handling of 177Lu-labelled pharmaceuticals implies an increase of the personnel exposure and this aspect is evaluated in this paper, in comparison with personal exposure in Y manipulation. MATERIALS AND METHODS: Personal dose measurements were performed during 26 177Lu-DOTATOC preparations by using a series of thin active layer LiF: Mg,Cu,P thermoluminescence dosimeters fixed at the operator's fingertips to evaluate the skin equivalent dose and by means of direct reading dosimeters positioned at the chest to evaluate the personal effective dose. Individual protection devices, such as shielded aprons and anti-X gloves, were also used. RESULTS: The 95th percentile of the skin equivalent dose distribution for 177Lu operations by using 0.20-mm anti-X gloves was 0.080 mSv/GBq for the chemist and 0.011 mSv/GBq for the physician, whereas the 75th percentile was 0.058 mSv/GBq for the chemist and 0.006 mSv/GBq for the physician. The use of the 0.25 mm Pb-equivalent anti-X apron halved the personal equivalent dose measured over the apron by a direct reading dosimeter. Skin doses were compared with Y-DOTATOC procedures: no relevant exposure reduction is observed for chemists, whereas doses are considerably lower during administration procedures performed by physicians. CONCLUSION: In this study, an evaluation of the skin equivalent doses during 177Lu-DOTATOC labelling and administration is presented. These data can be useful to assess the risk for workers in centres that are starting to implement PRRT using 177Lu. The use of appropriate protection devices and procedures allows the observance of International Commission for Radiological Protection dose limits for exposed workers.",
keywords = "Lu-DOTATOC, beta particles, DOTATOC, occupational exposure, radiation protection",
author = "Roberto Sghedoni and Elisa Grassi and Federica Fioroni and Mattia Asti and Vando Piccagli and Annibale Versari and Mauro Iori",
year = "2011",
month = "10",
doi = "10.1097/MNM.0b013e328349fd60",
language = "English",
volume = "32",
pages = "947--953",
journal = "Nuclear Medicine Communications",
issn = "0143-3636",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Personnel exposure in labelling and administration of 177Lu- DOTA-D-Phe1-Tyr3-octreotide

AU - Sghedoni, Roberto

AU - Grassi, Elisa

AU - Fioroni, Federica

AU - Asti, Mattia

AU - Piccagli, Vando

AU - Versari, Annibale

AU - Iori, Mauro

PY - 2011/10

Y1 - 2011/10

N2 - OBJECTIVE: The introduction of peptide receptor radionuclide therapy, mainly performed with Y and 177Lu-labelled somatostatin analogues, has widened the therapeutic horizon of nuclear medicine.The handling of 177Lu-labelled pharmaceuticals implies an increase of the personnel exposure and this aspect is evaluated in this paper, in comparison with personal exposure in Y manipulation. MATERIALS AND METHODS: Personal dose measurements were performed during 26 177Lu-DOTATOC preparations by using a series of thin active layer LiF: Mg,Cu,P thermoluminescence dosimeters fixed at the operator's fingertips to evaluate the skin equivalent dose and by means of direct reading dosimeters positioned at the chest to evaluate the personal effective dose. Individual protection devices, such as shielded aprons and anti-X gloves, were also used. RESULTS: The 95th percentile of the skin equivalent dose distribution for 177Lu operations by using 0.20-mm anti-X gloves was 0.080 mSv/GBq for the chemist and 0.011 mSv/GBq for the physician, whereas the 75th percentile was 0.058 mSv/GBq for the chemist and 0.006 mSv/GBq for the physician. The use of the 0.25 mm Pb-equivalent anti-X apron halved the personal equivalent dose measured over the apron by a direct reading dosimeter. Skin doses were compared with Y-DOTATOC procedures: no relevant exposure reduction is observed for chemists, whereas doses are considerably lower during administration procedures performed by physicians. CONCLUSION: In this study, an evaluation of the skin equivalent doses during 177Lu-DOTATOC labelling and administration is presented. These data can be useful to assess the risk for workers in centres that are starting to implement PRRT using 177Lu. The use of appropriate protection devices and procedures allows the observance of International Commission for Radiological Protection dose limits for exposed workers.

AB - OBJECTIVE: The introduction of peptide receptor radionuclide therapy, mainly performed with Y and 177Lu-labelled somatostatin analogues, has widened the therapeutic horizon of nuclear medicine.The handling of 177Lu-labelled pharmaceuticals implies an increase of the personnel exposure and this aspect is evaluated in this paper, in comparison with personal exposure in Y manipulation. MATERIALS AND METHODS: Personal dose measurements were performed during 26 177Lu-DOTATOC preparations by using a series of thin active layer LiF: Mg,Cu,P thermoluminescence dosimeters fixed at the operator's fingertips to evaluate the skin equivalent dose and by means of direct reading dosimeters positioned at the chest to evaluate the personal effective dose. Individual protection devices, such as shielded aprons and anti-X gloves, were also used. RESULTS: The 95th percentile of the skin equivalent dose distribution for 177Lu operations by using 0.20-mm anti-X gloves was 0.080 mSv/GBq for the chemist and 0.011 mSv/GBq for the physician, whereas the 75th percentile was 0.058 mSv/GBq for the chemist and 0.006 mSv/GBq for the physician. The use of the 0.25 mm Pb-equivalent anti-X apron halved the personal equivalent dose measured over the apron by a direct reading dosimeter. Skin doses were compared with Y-DOTATOC procedures: no relevant exposure reduction is observed for chemists, whereas doses are considerably lower during administration procedures performed by physicians. CONCLUSION: In this study, an evaluation of the skin equivalent doses during 177Lu-DOTATOC labelling and administration is presented. These data can be useful to assess the risk for workers in centres that are starting to implement PRRT using 177Lu. The use of appropriate protection devices and procedures allows the observance of International Commission for Radiological Protection dose limits for exposed workers.

KW - Lu-DOTATOC

KW - beta particles

KW - DOTATOC

KW - occupational exposure

KW - radiation protection

UR - http://www.scopus.com/inward/record.url?scp=80052443894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052443894&partnerID=8YFLogxK

U2 - 10.1097/MNM.0b013e328349fd60

DO - 10.1097/MNM.0b013e328349fd60

M3 - Article

C2 - 21876406

AN - SCOPUS:80052443894

VL - 32

SP - 947

EP - 953

JO - Nuclear Medicine Communications

JF - Nuclear Medicine Communications

SN - 0143-3636

IS - 10

ER -